AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

AstraZeneca reported a significant 77% surge in quarterly net profit, reaching $2.53 billion, driven by strong US growth and ...

Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator ...

Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and ...

Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales ...

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

Both Lilly and Novo are racing to bring oral versions of their blockbuster GLP-1 treatments to market. Novo's once-daily oral ...

AstraZeneca said revenue grew in the third quarter, boosted by the strength of the pharmaceutical giant's treatments pipeline. The U.K. company booked a 14% on-year increase in third-quarter core ...

UK's main stock indices were little changed on Thursday as sterling steadied near multi-month lows, with traders pausing for ...

British pharmaceutical giant AstraZeneca on Thursday said its net profit jumped 77 percent in the third quarter as the group expands its operations in the United States.

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...